Western blot analysis

YH Yung Chang Hsu
MC Mohane Selvaraj Coumar
WW Wen-Chieh Wang
HS Hui-Yi Shiao
YK Yi-Yu Ke
WL Wen-Hsing Lin
CK Ching-Chuan Kuo
CC Chun-Wei Chang
FK Fu-Ming Kuo
PC Pei-Yi Chen
SW Sing-Yi Wang
AL An-Siou Li
CC Chun-Hwa Chen
PK Po-Chu Kuo
CC Ching-Ping Chen
MW Ming-Hsine Wu
CH Chen-Lung Huang
KY Kuei-Jung Yen
YC Yun-I Chang
JH John T.-A. Hsu
CC Chiung-Tong Chen
TY Teng-Kuang Yeh
JS Jen-Shin Song
request Request a Protocol
ask Ask a question
Favorite

Western blot analysis was conducted as previously described [13]. Primary antibodies against phospho-FLT3 (Tyr591) (#3461) and phospho-AURKA (Thr288) (#3079) were purchased from Cell Signaling Technology. The anti-FLT3 antibody (sc-480) and anti-AURKA antibody (07–648) were purchased from Santa Cruz Biotechnology and Upstate, respectively. The anti-β-actin rabbit polyclonal antibody (GTX110564) was purchased from GeneTex (CA, USA). The secondary antibodies horseradish peroxidase (HRP)-linked goat anti-rabbit IgG (111-035-003) were purchased from Jackson Immuno (West Grove, PA, USA). MV4-11 cells were incubated with compound BPR1K871 for 2.0 h at the indicated concentrations. Cell lysates were prepared and analyzed by immunoblotting. For AURKA analysis, the cell lysates were obtained from MV4-11 cells incubated for 16 h with 40 ngmL-1 nocodazole, followed by drug treatment for 2.0 h at the indicated concentrations.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A